非酒精性脂肪性肝病代谢组学研究进展

Research advances in metabolomics in nonalcoholic fatty liver disease

非酒精性脂肪性肝病(NAFLD)发病率逐渐升高,已成为我国第一大慢性肝病的首要原因。目前对NAFLD的发病机制并未完全阐明且无特效药物。从发病机制、无创诊断、药物作用与疗效角度出发,介绍了以机体内源性小分子代谢物为研究对象的代谢组学在NAFLD中的研究进展,为进一步探索NAFLD提供新的思路与方法。

The incidence rate of nonalcoholic fatty liver disease(NAFLD)is gradually increasing,and NAFLD has become the most important chronic liver disease in China.At present,the pathogenesis of NAFLD has not been fully elucidated and there are still no effective drugs.From the perspectives of pathogenesis,noninvasive diagnosis,and drug action and efficacy,this article introduces the research advances in metabolomics regarding endogenous small molecule metabolites in NAFLD,so as to provide new ideas and methods for further exploration of NAFLD.